This inventor holds 2 USPTO granted patents, plus 1 CIPO patent. Top assignee: H Bion Co., Ltd.. Active years: 2014-2016.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2014-2016
Title: Sun-Jong Kim: Innovator in Stem Cell Research
Introduction
Sun-Jong Kim is a prominent inventor based in Anyang-si, South Korea. He has made significant contributions to the field of stem cell research, holding a total of 2 patents. His work focuses on the development of embryonic stem cell lines that have the potential to differentiate into various desired cell types.
Latest Patents
Sun-Jong Kim's latest patents include groundbreaking innovations in stem cell technology. One of his patents is titled "Neuro-progenitor produced from an SCNT-derived ES cell." This patent describes an embryonic stem cell line derived from a nucleus-transferred oocyte, which is prepared by transferring a nucleus of a human somatic cell into an enucleated human oocyte. This innovative approach allows for the differentiation of these cells into various desired cell types. Another patent, "Human embryonic stem cell line prepared by nuclear transfer of a human somatic cell into an enucleated human oocyte," outlines a similar process, emphasizing the versatility and potential applications of these stem cells.
Career Highlights
Sun-Jong Kim is currently associated with H Bion Co., Ltd., where he continues to advance his research in stem cell technology. His work has garnered attention in the scientific community, contributing to the understanding and application of stem cells in regenerative medicine.
Collaborations
Sun-Jong Kim has collaborated with notable colleagues in his field, including Sung-Il Roh and Woo-Suk Hwang. These collaborations have further enhanced the impact of his research and innovations.
Conclusion
Sun-Jong Kim is a key figure in the realm of stem cell research, with a focus on developing innovative embryonic stem cell lines. His contributions are paving the way for future advancements in regenerative medicine and cellular therapies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile